The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
Li
P K
PK
Department of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin.
Nicholls
M G
MG
Lai
K N
KN
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D015703:Antigens, CD / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D017252:CD3 Complex; D003524:Cyclosporins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D011948:Receptors, Antigen, T-Cell; D016559:Tacrolimus